Fig 2: Immunohistochemical expression of YAP1 in breast cancer. (A) Normal breast acini showing expression of YAP1 in myoepithelial cells and cytoplasmic expression in luminal cells (Immunoperoxidase, x400). (B) Ductal carcinoma in-situ (DCIS) showing cytoplasmic expression of YAP1 in ductal epithelial cells (Immunoperoxidase, x200). (C and D) Invasive ductal carcinoma, NST (luminal type) showing cytoplasmic and nuclear expression of YAP1 in tumor cells (Immunoperoxidase, x200).

Fig 3: YAP1 mRNA expression in the different molecular subtypes of breast cancer. qRT-PCR analysis showing significant increase in average YAP1 mRNA in luminal compared to TNBC (*P = 0.017).

Fig 4: Other factors are involved in CAR activation-induced hepatomegaly and liver regeneration. (A) The mRNA level of other related genes in wild-type mice treated by TCPOBOP or corn oil for 5 or 10 days. (B) The mRNA level of other related genes in wild-type or Yap–/– mice. (C) The protein levels of C-Myc, FOXM1 and MET were upregulated after treated by TCPOBOP for 5 or 10 days. (D) The protein levels of C-Myc, FOXM1, CTNNB1 and MET were upregulated after treated by TCPOBOP in Yap−/− mice. (E) Quantification of Western blot results in wild-type mice. (F) Quantification of Western blot results in Yap−/− mice. Data are presented as mean±SD, n = 5; ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001, significantly different to control; Student's t test.

Fig 5: (A) NANOG, OCT4 and SOX2 mRNA expression in breast cancer and control. (A) Transcript levels of NANOG, OCT4and SOX2 in breast cancer tissues and normal breast tissues quantified by qRT-PCR and presented as fold induction showing significant increase in NANOG and OCT4 in Breast cancer. *P < 0.05, **P < 0.01. (B) MCF-7 cells showing significant reduction in mRNA expression of YAP1, SOX2 and NANOG in response to VP treatment. *P < 0.05. (C) MDA-MB-231 cells showing reduction in expression of YAP1 and SOX2 and increase in NANOG in response to VP treatment. *P < 0.05.